Key facts
- This page summarizes Scott M. Coiante's Form 4 filing for Aprea Therapeutics, Inc. (APRE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Aug 2022, 17:00.
Scott M. Coiante - 28 Jul 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)
- Reporting relationship
- SVP, Chief Financial Officer
- Issuer ticker
- APRE
- Reported as of
- 28 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Aug 2022, 17:00:42 UTC
- Prior SEC filing
- 07 Jun 2022
- Next SEC filing
- 25 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott M. Coiante
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott M. Coiante filed Form 4 for Aprea Therapeutics, Inc. (APRE) on 01 Aug 2022.
Change
- Previous filing in this sequence was filed on 07 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APRE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +60,800
- Change %
- +72%
- Price
- $0.000000
- Shares after
- 145,065
- Date
- 28 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APRE
transaction
Derivative
Stock Option (right to Buy)
Award
- Transaction value
- $0
- Shares
- +89,200
- Change %
- Price
- $0.000000
- Shares after
- 89,200
- Date
- 28 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 89,200
- Exercise price
- $1.09
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 20,266 shares on July 28, 2023, (ii) 20,267 shares on July 28, 2024 and (iii) 20,267 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Footnote F2
Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.